Seminar Series: Dr. Flory Tsobo Muanda , PhD

Using administrative data to conduct a population-based drug safety study in older adults with low kidney function: lessons learned

Flory Tsobo Muanda, PhD

Assistant Professor
Department of Physiology and Pharmacology,
Department of Epidemiology & Biostatistics
Western University

Adjunct Scientist
Kidney, dialysis, and transplantation
IC/ES Western and IC/ES 

Affiliate Scientist
Lawson Health Research Institute

Short Biography:
Dr. Flory Tsobo Muanda is an adjunct scientist in the Kidney, Dialysis, and Transplantation (KDT) Program. He is a pharmacoepidemiologist and assistant professor at the Department of Physiology and Pharmacology and Epidemiology and Biostatistics at Western University. Dr. Muanda's research program aims to improve prescription drug safety for older adults. His particular focus is on older adults with chronic kidney disease, chronic liver disease, and those taking multiple medications. Dr. Muanda conducts population-based studies using Ontario’s administrative healthcare databases housed at ICES to inform safer prescribing practices for older adults, a segment of the population often excluded from clinical trials


In Canada, one in three older adults has chronic kidney disease (CKD), which makes them susceptible to medication toxicity due to the accumulation of medications with renal excretion in their bloodstream. As a result, product monographs and dosing guidelines recommend reducing the dosage or contraindicating such medications in high-risk CKD patients to prevent toxicity. However, these recommendations are based solely on pharmacokinetic studies that generally involve a small number of young patients. It is unknown whether these results apply to older adults. Additionally, case reports provide evidence of clinical outcomes among CKD patients to support these recommendations since older adults with chronic kidney disease are often excluded from clinical trials. Regulatory agencies such as the FDA and Health Canada rely on population-based studies utilizing large administrative databases to inform safe prescribing for older adults with low kidney function.

In this presentation, we will discuss lessons learned from population-based studies conducted over the last five years using Ontario's healthcare administrative databases. We will also provide two illustrative drug safety studies linking baclofen to encephalopathy in older adults with CKD.


Pharmacoepidemiology, drug safety, adverse drug events, pharmacokinetic


Date: Friday, November 10th
Time: 1:30 pm - 2:30 pm
Location: PHFM 3015 (Western Centre for Public Health and Family Medicine)